132 related articles for article (PubMed ID: 31646652)
1. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
3. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
4. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
5. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
6. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
[TBL] [Abstract][Full Text] [Related]
7. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
9. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis.
Liu KL; Fan JH; Wu J
Clin Lab; 2017 May; 63(5):871-880. PubMed ID: 28627814
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.
Illemann M; Laerum OD; Hasselby JP; Thurison T; Høyer-Hansen G; Nielsen HJ; ; Christensen IJ
Cancer Med; 2014 Aug; 3(4):855-64. PubMed ID: 24889870
[TBL] [Abstract][Full Text] [Related]
12. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
[TBL] [Abstract][Full Text] [Related]
13. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
[TBL] [Abstract][Full Text] [Related]
15. Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Lippert S; Berg KD; Høyer-Hansen G; Lund IK; Iversen P; Christensen IJ; Brasso K; Røder MA
Biomark Med; 2016; 10(2):209-16. PubMed ID: 26764285
[TBL] [Abstract][Full Text] [Related]
16. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
[TBL] [Abstract][Full Text] [Related]
17. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
[TBL] [Abstract][Full Text] [Related]
19. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).
Schultz M; Rasmussen LJH; Andersen MH; Stefansson JS; Falkentoft AC; Alstrup M; Sandø A; Holle SLK; Meyer J; Törnkvist PBS; Høi-Hansen T; Kjøller E; Jensen BN; Lind M; Ravn L; Kallemose T; Lange T; Køber L; Rasmussen LS; Eugen-Olsen J; Iversen KK
Scand J Trauma Resusc Emerg Med; 2018 Aug; 26(1):69. PubMed ID: 30153859
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
